322 related articles for article (PubMed ID: 30884782)
21. Beware the Medical-Industrial Complex.
Stevens CW; Glatstein E
Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
[TBL] [Abstract][Full Text] [Related]
22. (Re)imagining purpose: A framework for sustainable nanotechnology innovation.
Jeffcoat P; Di Lernia C; Hardy C; New EJ; Chrzanowski W
NanoImpact; 2024 May; 35():100511. PubMed ID: 38750963
[TBL] [Abstract][Full Text] [Related]
23. Drug Delivery Technology Development in Canada.
Wasan KM; Badea I
Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31627471
[TBL] [Abstract][Full Text] [Related]
24. Drug delivery system innovation and Health Technology Assessment: Upgrading from Clinical to Technological Assessment.
Panzitta M; Bruno G; Giovagnoli S; Mendicino FR; Ricci M
Int J Pharm; 2015 Nov; 495(2):1005-18. PubMed ID: 26399633
[TBL] [Abstract][Full Text] [Related]
25. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
26. Electrosprayed Myocet-like Liposomes: An Alternative to Traditional Liposome Production.
Collier MA; Bachelder EM; Ainslie KM
Pharm Res; 2017 Feb; 34(2):419-426. PubMed ID: 27896588
[TBL] [Abstract][Full Text] [Related]
27. H2020 EU Research & Innovation Program Boost the Transfer of Technological Breakthroughs, Enable New Solutions for Personalised Health and Impact the Industry and Healthcare Systems.
Smit PH; Lymberis A
Stud Health Technol Inform; 2015; 211():3-17. PubMed ID: 25980846
[TBL] [Abstract][Full Text] [Related]
28. Research on cancer diagnosis in Malaysia: current status.
Looi LM; Zubaidah Z; Cheah PL; Cheong SK; Gudum HR; Iekhsan O; Ikram SI; Jamal R; Mak JW; Othman NH; Puteri JN; Rosline H; Sabariah AR; Seow HF; Sharifah NA;
Malays J Pathol; 2004 Jun; 26(1):13-27. PubMed ID: 16190103
[TBL] [Abstract][Full Text] [Related]
29. Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases.
Oku N
Biol Pharm Bull; 2017; 40(2):119-127. PubMed ID: 28154249
[TBL] [Abstract][Full Text] [Related]
30. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
31. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
32. Liposomal systems as viable drug delivery technology for skin cancer sites with an outlook on lipid-based delivery vehicles and diagnostic imaging inputs for skin conditions'.
Akhtar N; Khan RA
Prog Lipid Res; 2016 Oct; 64():192-230. PubMed ID: 27697511
[TBL] [Abstract][Full Text] [Related]
33. Liposomes in biology and medicine.
Schwendener RA
Adv Exp Med Biol; 2007; 620():117-28. PubMed ID: 18217339
[TBL] [Abstract][Full Text] [Related]
34. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
35. Vincristine liposomal--INEX: lipid-encapsulated vincristine, onco TCS, transmembrane carrier system--vincristine, vincacine, vincristine sulfate liposomes for injection, VSLI.
Drugs R D; 2004; 5(2):119-23. PubMed ID: 15293876
[TBL] [Abstract][Full Text] [Related]
36. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
Allen D; Gillen E; Rixson L
JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
[TBL] [Abstract][Full Text] [Related]
37. The Wyss institute: A new model for medical technology innovation and translation across the academic-industrial interface.
Tolikas M; Antoniou A; Ingber DE
Bioeng Transl Med; 2017 Sep; 2(3):247-257. PubMed ID: 29313034
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in liposomal nanohybrid cerasomes as promising drug nanocarriers.
Yue X; Dai Z
Adv Colloid Interface Sci; 2014 May; 207():32-42. PubMed ID: 24368133
[TBL] [Abstract][Full Text] [Related]
39. Advantages of liposomal delivery systems for anthracyclines.
Allen TM; Martin FJ
Semin Oncol; 2004 Dec; 31(6 Suppl 13):5-15. PubMed ID: 15717735
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
